Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
Bolstering neuroscience push with late-stage Tourette therapy
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Expanded indication makes Stelo the first FDA-cleared OTC CGM for children aged two years and older with diabetes or prediabetes
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
Broadening access for children & patients with inhibitor-complicated hemophilia
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
